Adding Entecavir to Tenofovir/FTC Works in Some HIV/HBV-Coinfected Patients

But the study was small, and the success of the intervention may be attributable to the low baseline rate of 3TC resistance.

Tenofovir/FTC constitutes first-line therapy for hepatitis B virus (HBV) infection in HIV-coinfected patients. However, some patients have incomplete HBV suppression on this regimen. In a single-arm, prospective, observational study, investigators evaluated whether such patients might benefit from the addition of entecavir to their current therapy.

Thirteen patients who had failed to suppress HBV DNA after at least 6 months of tenofovir/FTC were included in the study. The median baseline HBV DNA level — 2814 IU/mL — was relatively low and may reflect partial suppression of HBV replication by tenofovir/FTC. Seven patients had received 3TC monotherapy before starting tenofovir/FTC. Only one of eight patients who underwent baseline HBV resistan…

Reviewing Author

Rajesh T. Gandhi, MD

Adding Entecavir to Tenofovir/FTC Works in Some HIV/HBV-Coinfected Patients

Topics

Reviewing Author